GlaxoSmithKline and Genmab announce top-line results for ofatumumab in rheumatoid arthritis

GSK and Genmab A/S announced today preliminary top-line results from a Phase III study of ofatumumab administered intravenously for the treatment of rheumatoid arthritis (RA) in patients who had an inadequate response to methotrexate.